Cargando…

A Narrative Review Discussing the Efficiency of Personalized Dosing Algorithm of Follitropin Delta for Ovarian Stimulation and the Reproductive and Clinical Outcomes

Background: Follitropin delta is the third recombinant human follicle-stimulating hormone (r-hFSH) expressed in a host cell line of human fetal retinal origin that currently emphasizes that the actual tendency of administration is a personalized dosing algorithm based on the anti-Müllerian hormone (...

Descripción completa

Detalles Bibliográficos
Autores principales: Doroftei, Bogdan, Ilie, Ovidiu-Dumitru, Anton, Nicoleta, Marcu, Olivia-Andreea, Scripcariu, Ioana-Sadyie, Ilea, Ciprian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9858569/
https://www.ncbi.nlm.nih.gov/pubmed/36672987
http://dx.doi.org/10.3390/diagnostics13020177
_version_ 1784874134499491840
author Doroftei, Bogdan
Ilie, Ovidiu-Dumitru
Anton, Nicoleta
Marcu, Olivia-Andreea
Scripcariu, Ioana-Sadyie
Ilea, Ciprian
author_facet Doroftei, Bogdan
Ilie, Ovidiu-Dumitru
Anton, Nicoleta
Marcu, Olivia-Andreea
Scripcariu, Ioana-Sadyie
Ilea, Ciprian
author_sort Doroftei, Bogdan
collection PubMed
description Background: Follitropin delta is the third recombinant human follicle-stimulating hormone (r-hFSH) expressed in a host cell line of human fetal retinal origin that currently emphasizes that the actual tendency of administration is a personalized dosing algorithm based on the anti-Müllerian hormone (AMH) and body mass index (BMI) for ovarian stimulation. Methods: In this context, we aimed, in the present manuscript, to gather all available data published between 2018–2022 regarding the co-administration and administration of follitropin delta and the clinical outcomes reported following an in vitro fertilization (IVF). Results: Follitropin delta is non-inferior in contrast to its previously launched agents for ovarian stimulation, enhancing a similar-to-superior response reflected by both the reproductive and pregnancy outcomes in parallel with a low risk of ovarian hyperstimulation syndrome (OHSS), being well tolerated. The body weight and AMH level are factors that may influence the outcome in a patient. Despite controversy and results that refute these arguments on several occasions, follitropin delta exceeds the benefits of conventional dosing with either follitropin alfa or follitropin beta. Thus, all post hoc, derived analyses and subsets of patients that participated in subsequent studies support this statement. Conclusions: Despite the relatively limited spectrum of data in the current literature, most authors brought potent proof, supporting the subsequent use of this drug depending on the patient’s profile and overcoming ethnic-related limitations. Although others contradict these observations, this topic and drug possess substantial potential, which is why additional studies are mandatory to fill the existing gaps in our knowledge and expand these experiences at a larger scale supported by the obtained reproductive and clinical outcomes that clearly indicate an overcoming of all limitations.
format Online
Article
Text
id pubmed-9858569
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-98585692023-01-21 A Narrative Review Discussing the Efficiency of Personalized Dosing Algorithm of Follitropin Delta for Ovarian Stimulation and the Reproductive and Clinical Outcomes Doroftei, Bogdan Ilie, Ovidiu-Dumitru Anton, Nicoleta Marcu, Olivia-Andreea Scripcariu, Ioana-Sadyie Ilea, Ciprian Diagnostics (Basel) Review Background: Follitropin delta is the third recombinant human follicle-stimulating hormone (r-hFSH) expressed in a host cell line of human fetal retinal origin that currently emphasizes that the actual tendency of administration is a personalized dosing algorithm based on the anti-Müllerian hormone (AMH) and body mass index (BMI) for ovarian stimulation. Methods: In this context, we aimed, in the present manuscript, to gather all available data published between 2018–2022 regarding the co-administration and administration of follitropin delta and the clinical outcomes reported following an in vitro fertilization (IVF). Results: Follitropin delta is non-inferior in contrast to its previously launched agents for ovarian stimulation, enhancing a similar-to-superior response reflected by both the reproductive and pregnancy outcomes in parallel with a low risk of ovarian hyperstimulation syndrome (OHSS), being well tolerated. The body weight and AMH level are factors that may influence the outcome in a patient. Despite controversy and results that refute these arguments on several occasions, follitropin delta exceeds the benefits of conventional dosing with either follitropin alfa or follitropin beta. Thus, all post hoc, derived analyses and subsets of patients that participated in subsequent studies support this statement. Conclusions: Despite the relatively limited spectrum of data in the current literature, most authors brought potent proof, supporting the subsequent use of this drug depending on the patient’s profile and overcoming ethnic-related limitations. Although others contradict these observations, this topic and drug possess substantial potential, which is why additional studies are mandatory to fill the existing gaps in our knowledge and expand these experiences at a larger scale supported by the obtained reproductive and clinical outcomes that clearly indicate an overcoming of all limitations. MDPI 2023-01-04 /pmc/articles/PMC9858569/ /pubmed/36672987 http://dx.doi.org/10.3390/diagnostics13020177 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Doroftei, Bogdan
Ilie, Ovidiu-Dumitru
Anton, Nicoleta
Marcu, Olivia-Andreea
Scripcariu, Ioana-Sadyie
Ilea, Ciprian
A Narrative Review Discussing the Efficiency of Personalized Dosing Algorithm of Follitropin Delta for Ovarian Stimulation and the Reproductive and Clinical Outcomes
title A Narrative Review Discussing the Efficiency of Personalized Dosing Algorithm of Follitropin Delta for Ovarian Stimulation and the Reproductive and Clinical Outcomes
title_full A Narrative Review Discussing the Efficiency of Personalized Dosing Algorithm of Follitropin Delta for Ovarian Stimulation and the Reproductive and Clinical Outcomes
title_fullStr A Narrative Review Discussing the Efficiency of Personalized Dosing Algorithm of Follitropin Delta for Ovarian Stimulation and the Reproductive and Clinical Outcomes
title_full_unstemmed A Narrative Review Discussing the Efficiency of Personalized Dosing Algorithm of Follitropin Delta for Ovarian Stimulation and the Reproductive and Clinical Outcomes
title_short A Narrative Review Discussing the Efficiency of Personalized Dosing Algorithm of Follitropin Delta for Ovarian Stimulation and the Reproductive and Clinical Outcomes
title_sort narrative review discussing the efficiency of personalized dosing algorithm of follitropin delta for ovarian stimulation and the reproductive and clinical outcomes
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9858569/
https://www.ncbi.nlm.nih.gov/pubmed/36672987
http://dx.doi.org/10.3390/diagnostics13020177
work_keys_str_mv AT dorofteibogdan anarrativereviewdiscussingtheefficiencyofpersonalizeddosingalgorithmoffollitropindeltaforovarianstimulationandthereproductiveandclinicaloutcomes
AT ilieovidiudumitru anarrativereviewdiscussingtheefficiencyofpersonalizeddosingalgorithmoffollitropindeltaforovarianstimulationandthereproductiveandclinicaloutcomes
AT antonnicoleta anarrativereviewdiscussingtheefficiencyofpersonalizeddosingalgorithmoffollitropindeltaforovarianstimulationandthereproductiveandclinicaloutcomes
AT marcuoliviaandreea anarrativereviewdiscussingtheefficiencyofpersonalizeddosingalgorithmoffollitropindeltaforovarianstimulationandthereproductiveandclinicaloutcomes
AT scripcariuioanasadyie anarrativereviewdiscussingtheefficiencyofpersonalizeddosingalgorithmoffollitropindeltaforovarianstimulationandthereproductiveandclinicaloutcomes
AT ileaciprian anarrativereviewdiscussingtheefficiencyofpersonalizeddosingalgorithmoffollitropindeltaforovarianstimulationandthereproductiveandclinicaloutcomes
AT dorofteibogdan narrativereviewdiscussingtheefficiencyofpersonalizeddosingalgorithmoffollitropindeltaforovarianstimulationandthereproductiveandclinicaloutcomes
AT ilieovidiudumitru narrativereviewdiscussingtheefficiencyofpersonalizeddosingalgorithmoffollitropindeltaforovarianstimulationandthereproductiveandclinicaloutcomes
AT antonnicoleta narrativereviewdiscussingtheefficiencyofpersonalizeddosingalgorithmoffollitropindeltaforovarianstimulationandthereproductiveandclinicaloutcomes
AT marcuoliviaandreea narrativereviewdiscussingtheefficiencyofpersonalizeddosingalgorithmoffollitropindeltaforovarianstimulationandthereproductiveandclinicaloutcomes
AT scripcariuioanasadyie narrativereviewdiscussingtheefficiencyofpersonalizeddosingalgorithmoffollitropindeltaforovarianstimulationandthereproductiveandclinicaloutcomes
AT ileaciprian narrativereviewdiscussingtheefficiencyofpersonalizeddosingalgorithmoffollitropindeltaforovarianstimulationandthereproductiveandclinicaloutcomes